Evidence map›Paper›PMID 40013147›Full record

ArticleFrontiers in immunology2025

Advanced disease and CD8

Eva Tranter, David Busch, Clarissa Heck, Igor Wolfgang Blau, Axel Nogai, Phillip Schiele, Christian Meisel, Lars Bullinger, Marco Frentsch, Il-Kang Na

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eva TranterCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
David BuschCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
Clarissa HeckCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
Igor Wolfgang BlauCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
Axel NogaiOnkologische Schwerpunktpraxis Tiergarten, Berlin, Germany.
Phillip SchieleCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
Christian MeiselBerlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany.
Lars BullingerCharité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
Marco Frentsch *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.
Il-Kang Na *Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Infections are a major cause of early morbidity and mortality in patients with multiple myeloma (MM) who are characterized by immunodeficiency secondary to disease. However, prospectively collected data on infection risk in this population are scarce. We aimed at identifying parameters in monoclonal gammopathy of undetermined significance (MGUS) and newly diagnosed MM (NDMM) patients with predictive power for early severe infections (SI). Methods: We conducted a prospective study with newly diagnosed MGUS and NDMM patients. Besides clinical and laboratory data, immune parameters were collected at initial diagnosis before therapy initiation. Primary endpoint was the occurrence of SI within 12 months after diagnosis. Results: 45% of patients developed infection, 26% with SI. Four main risk factors for SI were identified: ECOG ≥ 2 (p < 0.001), ISS stage II/III (p = 0.002), therapeutic intervention (p < 0.001), and elevated CD8 Conclusion: We developed a straightforward risk score that considers the relevance of T cell fitness in MGUS and NDMM patients and can help physicians to identify patients at risk of infection, thus enabling the implementation of timely and individualized prevention strategies.

Indexed as

CD8-Positive T-LymphocytesInfectionsMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsinfectionMGUSMultiple Myelomarisk scoresecondary immunodeficiency

Identifiers

PMID40013147
PMCPMC11862831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.